Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 2 OTHER 1 NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Stomach Neoplasms 1 Salivary Gland Neoplasms 1 Neoplasm Metastasis 1 Lung Neoplasms 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Cholangiocarcinoma 1 Carcinosarcoma 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

Carboplatin 41 Cisplatin 38 Paclitaxel 34 Specimen Handling 32 Radiotherapy 27 Magnetic Resonance Spectroscopy 25 Gemcitabine 23 Vinorelbine 15 Etoposide 15 Docetaxel 15 Biopsy 13 Pemetrexed 10 Cyclophosphamide 10 pembrolizumab 9 Taxes 9 Immunoglobulin G 9 Disulfides 9 Platinum 8 1,2-diaminocyclohexaneplatinum II citrate 8 X-Rays 7 Vinblastine 7 Erlotinib Hydrochloride 7 osimertinib 6 durvalumab 6 atezolizumab 6 Nivolumab 6 Irinotecan 6 Ifosfamide 6 Chemotherapy, Adjuvant 6 Celecoxib 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

NIH × Lung Neoplasms × ceralasertib × Clear all

NCT06732401 2026-05-13

CLEAR

National Cancer Institute (NCI)

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡